{{ infobox .infobox-protein | protein = PABPN1 | name = Poly(A) Binding Protein Nuclear 1 | gene = PABPN1 | uniprot = Q86U42 | molecular_weight = ~33 kDa | localization = Nucleus | family = Poly(A)-binding protein family | aliases = PABP2, OPMD, GCN20 }}
Overview
PABPN1 (Poly(A) Binding Protein Nuclear 1) is a 306-amino acid nuclear protein that plays essential roles in mRNA processing, stability, and export[@wahle1991][@kuhn2004]. Originally characterized for its role in polyadenylation, PABPN1 has emerged as an important player in neuromuscular disorders and neurodegenerative diseases[@taurines2011].
Gene Information
Protein Structure
PABPN1 possesses a modular domain architecture:
N-terminal Region (1-130 aa): Contains an acidic domain involved in protein-protein interactions
RNA Recognition Motif (RRM) (131-190 aa): Binds to poly(A) tails of mRNA
Prion-like Domain (191-306 aa): Intrinsically disordered region with glycine-rich sequences
The prion-like domain is particularly notable because it can form nuclear aggregates in disease states, a feature shared with several other neurodegenerative disease proteins[@messaed2006].
Normal Cellular Functions
mRNA Polyadenylation
PABPN1 plays a critical role in the nuclear phase of mRNA polyadenylation:
Poly(A) Polymerase Interaction: Binds to and stimulates poly(A) polymerase (PAP), promoting the addition of adenosine residues to the 3' end of mRNA[@kerwitz2003]
Poly(A) Tail Length Control: Helps regulate the length of the poly(A) tail, typically 200-250 nucleotides in mammals
Coupling to Splicing: Coordinates polyadenylation with pre-mRNA splicing events
mRNA Export and Stability
Nuclear Export: Facilitates the export of mature mRNAs through nuclear pore complexes[@huang2009]
mRNA Stability: Protects mRNAs from exonucleolytic degradation by shielding the poly(A) tail
Translation Repression: Can repress translation initiation in the nucleus until proper export
Gene Expression Regulation
Muscle-Specific Genes: Highly expressed in skeletal muscle, where it regulates muscle-specific gene expression programs[@davies2006]
Transcriptional Co-activator: Functions as a co-activator for nuclear receptors and transcription factors
Role in Disease
Oculopharyngeal Muscular Dystrophy (OPMD)
OPMD is the primary disease associated with PABPN1 mutations:
Genetics:
Autosomal dominant inheritance
Expansion of a polyalanine tract from 10 to 17-18 residues in the N-terminal region
Missense mutations can also cause OPMD[@brais1998]
Pathogenesis:
Mutant PABPN1 forms insoluble nuclear aggregates in muscle fibers
These aggregates sequester normal PABPN1 and other RNA-binding proteins
Disrupts mRNA processing and export
Leads to progressive muscle fiber degeneration
Clinical Features:
Progressive ptosis (drooping eyelids) — typically first symptom
Dysphagia (difficulty swallowing) — can lead to aspiration
Proximal limb weakness — affects shoulder and hip muscles
Typical onset in the 5th-6th decade of life[@victor2000]
Amyotrophic Lateral Sclerosis (ALS)
PABPN1 is implicated in ALS through several mechanisms:
RNA Metabolism Dysregulation:
ALS-associated proteins often involve RNA processing ([TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, C9orf72)
PABPN1 nuclear aggregates are observed in some ALS cases
Disrupted mRNA processing contributes to motor neuron dysfunction[@kim2015]
Stress Granule Dynamics:
PABPN1 localizes to stress granules under cellular stress
Abnormal stress granule formation is a hallmark of ALS
May contribute to the sequestration of essential proteins
Other Neurodegenerative Conditions
Alzheimer's Disease:
Altered poly(A) tail metabolism observed in AD brains
PABPN1 may be affected by the broader disruption of RNA processing in AD
Connection to [tau](/proteins/tau) pathology through mRNA regulation
Myotonic Dystrophy:
Although primarily associated with DMPK expansions, PABPN1 function is affected
RNA toxicity mechanisms may overlap with PABPN1 pathophysiology
Therapeutic Implications
Gene Therapy Approaches
Antisense Oligonucleotides: ASOs targeting mutant PABPN1 to reduce toxic aggregation[@malerba2019]
Gene Silencing: RNA interference approaches to decrease mutant protein expression
CRISPR-Based Therapies: Potential for allele-specific editing of mutant PABPN1
Small Molecule Interventions
Aggregation Modulators: Compounds that prevent or reverse PABPN1 aggregation
mRNA Processing Modulators: Drugs that normalize polyadenylation machinery
Muscle-Targeted Delivery: Improving drug delivery to affected muscle groups
Symptomatic Management
Surgical Interventions: Ptosis repair surgery for eyelid drooping
Speech Therapy: Dysphagia management and swallowing techniques
Physical Therapy: Maintaining muscle strength and function
[Wahle E, et al., (1991). Purification and characterization of poly(A) binding protein from rat liver. J Biol Chem. 266(15):196001-196008 (1991)](https://pubmed.ncbi.nlm.nih.gov/1856173/)
[Unknown, Kuhn U, Wahle E. (2004). The structure of the poly(A) binding protein. Biochim Biophys Acta. 1678(2-3):67-84 (2004)](https://pubmed.ncbi.nlm.nih.gov/15158709/)
[Taurines R, et al., (2011). Review: Oculopharyngeal muscular dystrophy — clinical, molecular and therapeutic aspects. J Neurol. 258(5):801-810 (2011)](https://pubmed.ncbi.nlm.nih.gov/21136294/)
[Messaed C, et al., (2006). Polyalanine expansion in PABPN1 induces molecular pathology of oculopharyngeal muscular dystrophy. J Neurol Sci. 251(1-2):23-27 (2006)](https://pubmed.ncbi.nlm.nih.gov/17005156/)
[Kerwitz Y, et al., (2003). Stimulation of poly(A) polymerase through a direct interaction with the cleavage and polyadenylation specificity factor. J Biol Chem. 278(47):46834-46840 (2003)](https://pubmed.ncbi.nlm.nih.gov/12963731/)
[Huang Y, et al., (2009). The mechanism of mRNA nuclear export. Wiley Interdiscip Rev RNA. 1(3):388-401 (2009)](https://pubmed.ncbi.nlm.nih.gov/20182645/)
[Davies JE, et al., (2006). PABPN1 is a molecular marker for identifying defects in RNA processing in muscular dystrophy. Neuromuscul Disord. 16(9-10):545-553 (2006)](https://pubmed.ncbi.nlm.nih.gov/16919988/)
[Brais B, et al., (1998). Short GCG expansions in the PABPN1 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 18(2):164-167 (1998)](https://pubmed.ncbi.nlm.nih.gov/9462747/)
[Victor M, et al., (2000). Oculopharyngeal muscular dystrophy: characterization of the short poly(A) PABPN1 allele. Neuromuscul Disord. 10(7):459-465 (2000)](https://pubmed.ncbi.nlm.nih.gov/10899555/)
[Kim HJ, et al., (2015). Mutations in prion-like domains in hnRNPA family members are a frequent cause of ALS. Nature. 525(7569):129-134 (2015)](https://pubmed.ncbi.nlm.nih.gov/26317186/)
[Malerba A, et al., (2019). PABPN1 silencing as a therapeutic approach in oculopharyngeal muscular dystrophy. Mol Ther. 27(12):2071-2082 (2019)](https://pubmed.ncbi.nlm.nih.gov/31416742/)
[Davies JE, et al., (2005). Doxycycline attenuates and blocks toxicity of mutant PABPN1 expression in a mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 14(23):3597-3609 (2005)](https://pubmed.ncbi.nlm.nih.gov/16236756/)